We are a nimble scientific and technology communications group that marries highly credentialed medical content with targeted messaging across all phases of product development. From the identification of, and liaising with, clinical/scientific subject matter experts (SME's) or via the leveraging of real-time HCP survey methodologies, MIG uncovers and distills unique actionable scientific insights while supporting the spectrum of our partner's strategic communications needs. Approaches include the novel - unique qualitative one-on-one SME intelligence gathering or customized quantitative digital healthcare survey supported research - as well as the more traditional, including live or virtual medical advisories/Sci-exchanges, deep-dive literature map driven narrative support, Scientific platform creation with related internal team alignment, comprehensive compartmentalized slide libraries, "reasons to believe molecular and MOA story boards", as well as custom monograph creation and peer review publishing editorial support.M.I.G. applies science & novel technologies as communication solutions for our partners in the bio and gene technology spaces, while also supporting key clients within the complex sterile injectable, compounding, and pharmaceutical spheres. We create, hone, reformulate, and expertly format key scientific content and related strategic messaging. MIG typically receives project/program requests, from both new and long-time colleagues, in response to their team's needs for custom, often urgent, usually "n=1"- type solutions. They seek us out because they trust that we will figure it out, communicate back to them an effective plan of execution, and then just get the work done. Our partners appreciate our no-nonsense commitment, consistency, and professional approach, as well as our extensive experience with multiple regulatory processes at a myriad of partnering organizations, with resultant smooth program review and approval.Our emphasis is on the SCIENCE. Additionally we offer uncommon speed, quality, and service to support our current high-level competencies in the following specialty areas: gene technology, complex sterile injectables, Parkinson's, epilepsy, pain medicine, migraine, ADHD, hematology/oncology (including palliative medicine), nephrology, immunology, cardiology, sleep medicine, psychiatry, critical care, surgery, hospital & specialty pharmacy, gastroenterology, rheumatology, infectious disease, as well as educational programming and asset development for orphan diseases and animal health.